PMID- 25095534
OWN - NLM
STAT- MEDLINE
DCOM- 20140909
LR  - 20140806
IS  - 0890-9016 (Print)
IS  - 0890-9016 (Linking)
DP  - 2013
TI  - Impact of solid phase antibody testing on organ allocation in the United States.
PG  - 393-8
AB  - The implementation of the solid phase antibody assays has allowed for the 
      detection and characterization of human leukocyte antigen (HLA) specific 
      antibodies with greater sensitivity and specificity. This information can then be 
      used along with the donor's HLA typing to predict crossmatch results (a virtual 
      crossmatch). Using these data and the level of immunological risk assessed to the 
      antibodies detected, the determination of unacceptable antigens can be made. The 
      calculated panel reactive antibody (CPRA) provides for a means to determine the 
      frequency of these unacceptable antigens in the donor population and thereby 
      predict the probability of a positive crossmatch. In 2009, the Organ Procurement 
      Transplant Network administered by the United Network for Organ Sharing adopted 
      the CPRA as the means to define sensitization and to assign allocation points. 
      Follow-up studies have shown that the number of organ offers refused due to a 
      positive crossmatch has decreased significantly and has saved money through the 
      elimination of unnecessary testing. An additional benefit has been the increased 
      number of sensitized patients being transplanted successfully. Through technical 
      improvements and the refined interpretation of the solid phase antibody assays, 
      continual progress is being made in the definition of the unacceptable antigens 
      and the ability to transplant sensitized patients.
FAU - Reinsmoen, Nancy L
AU  - Reinsmoen NL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Transpl
JT  - Clinical transplants
JID - 8812419
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Enzyme-Linked Immunosorbent Assay/methods/trends
MH  - Flow Cytometry/methods/trends
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Testing/*methods/trends
MH  - Humans
MH  - *Organ Transplantation
MH  - Resource Allocation
MH  - Sensitivity and Specificity
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
MH  - United States
EDAT- 2013/01/01 00:00
MHDA- 2014/09/10 06:00
CRDT- 2014/08/07 06:00
PHST- 2014/08/07 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
PST - ppublish
SO  - Clin Transpl. 2013:393-8.